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The intestinal tract is a recognized reservoir of antibiotic-resistant organisms (ARO), and a potential target for strategies to reduce 
ARO colonization. Microbiome therapies such as fecal microbiota transplantation (FMT) have been established as an effective treat-
ment for recurrent Clostridioides difficile infection and may be an effective approach for reducing intestinal ARO colonization. In 
this article, we review the current published literature on the role of FMT for eradication of intestinal ARO colonization, review the 
potential benefit and limitations of the use of FMT in this setting, and outline a  research agenda for the future study of FMT for 
intestinal ARO colonization.
Keywords: antibiotic resistance; antibiotic-resistant organism; fecal microbiota transplantation; hospital epidemiology; 
microbiome; multidrug-resistant organisms; resistome.
The US Centers for Disease Control and Prevention has estimated 
that each year >2  000  000 patients are infected with antibiotic-
resistant organisms (AROs) and 23 000 die of these infections [1]. 
Infections due to AROs represent an urgent threat to public health 
and rates of antibiotic resistance are increasing faster than the de-
velopment of new antimicrobials [2, 3]. The intestinal tract can 
function as a reservoir for AROs, meaning AROs can be present 
without causing clinical symptoms [4]. Patients who are colonized 
with AROs are at risk of ARO infection and ARO transmission 
to other individuals (Figure 1) [5]. Although aggressive infec-
tion prevention interventions can help reduce their spread, these 
efforts do not control the source of ARO colonization [6, 7].
Multiple studies have used antimicrobials in an attempt to re-
duce ARO colonization or infection. However, demonstration of 
improvement in clinical end points has been inconsistent. The 
use of antimicrobials may also have unintended consequences of 
selection and expansion of AROs [8–11]. Thus, existing strategies 
can perpetuate a vicious cycle of increasing antimicrobial use, 
and pressure for expansion of antimicrobial resistance.
The intestinal microbiome of healthy patients is often 
characterized as diverse and resistant to ARO colonization. This 
protection from ARO colonization has bolstered enthusiasm for 
study of fecal microbiome therapeutics as an antibiotic-sparing 
approach to address antimicrobial resistance [5]. In the current 
article, we review published data on the role of fecal microbiota 
transplantation (FMT) for ARO control, summarize reported 
clinical outcomes data for the use of FMT to directly reduce 
ARO colonization, and outline a research agenda for advancing 
understanding of FMT for this application.
ARO COLONIZATION AS A COMPLEX PHENOMENON
Studies of ARO colonization have used different definitions 
of colonization and loss of colonization. This complicates 
the interpretation of estimates across settings. The detection 
of even a single isolate with a transmissible resistance mech-
anism is likely to have important public-health implications. 
However, the minimum criteria for colonization may lack spec-
ificity and in some cases may be overly sensitive. On the other 
hand, definitions of loss of colonization have also varied and 
may not be sensitive enough. Documentation with 3 consecu-
tive negative stool or rectal swab cultures is frequently used to 
define loss of colonization, but some investigators have used a 
single negative result or ≥2 negative consecutive stool or rectal 
swab cultures [12, 13]. Further complicating these definitions 
is the fact that intermittent fecal ARO detection after negative 
cultures has been described in multiple studies [13–15]. The 
potential limitations in sensitivity of detection of colonization 
was further underscored in 1 study with findings suggesting 
that vancomycin-resistant Enterococcus (VRE) colonization was 
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electrophoresis, even in “cleared” patients 5  years after initial 
detection [16].
Most published active surveillance studies of intestinal 
ARO colonization demonstrate themes of prolonged coloni-
zation, intermittent periods of shedding, variability in isolate 
recovery patterns by culture method and by ARO type, and 
codetection of multiple AROs [14, 17–21]. The duration of 
colonization also varies by ARO type. The reported median 
duration of colonization was 306 days (range, 1–1393 days) 
for VRE in 1 study [14] and 144  days (41–359  days) for 
multidrug-resistant gram-negative bacteria in another 
study [17], and the medians for carbapenem-resistant 
Enterobacteriaceae (CRE) in 2 studies were 165 and 295 days 
[19, 20]. Compared with patients with a single admission, 
those readmitted to hospitals or post–acute care facilities 
have been observed to have variable durations of coloniza-
tion [20]. The majority of published studies documenting 
the duration of ARO colonization have investigated out-
break scenarios or patients in acute care or post–acute care 
facilities, where apparently persistent ARO colonization may 
be due to ongoing ARO exposures and recolonization [22]. 
The variability in the natural history of ARO colonization 
makes decolonization outcomes after FMT challenging to 
interpret.
Data on the frequency of patient outcomes after ARO coloni-
zation are mixed but important to quantify. The development of 
United States Food and Drug Administration (FDA)–approved 
treatments for decolonization may rely on improving outcomes 
such as ARO infection. VRE colonization precedes infection 
in immunocompromised patients [23]. Isendahl et al [24] re-
ported population-level frequency estimates of bloodstream in-
fection among patients with urine or fecal extended-spectrum 
β-lactamase (ESBL)–producing Enterobacteriaceae coloni-
zation. Of patients with ESBL bloodstream infections, 98.6% 
had antecedent urine or stool colonization [24]. More work is 
needed to better determine which patients who are colonized 
with AROs will become infected and to estimate the number of 
colonized patients needed to treat to prevent infection, hospi-
talization, mortality, and other patient-centered outcomes.
THE HUMAN INTESTINAL MICROBIOME 
AS A THERAPEUTIC TARGET FOR ARO 
DECOLONIZATION
Although it is well established that anaerobic bacteria residing 
in the intestine can limit ARO colonization, the ideal strategy to 
modify intestinal microbiomes has not been defined. For decades, 
the association of antibiotic administration and subsequent ARO 














Figure 1. Concept illustration of intestinal microbial diversity as a protective factor against colonization with antibiotic-resistant organisms (AROs), adapted from Halpin 
et al [25]. Antibiotic exposure can lead to disruption of these community structures and subsequent colonization and dominance by AROs, which may increase risk of infec-
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mediated by off-target loss of anaerobic taxa as a consequence of 
antianaerobic antimicrobial activity [17, 18, 24, 26]. This principle 
was demonstrated by Donskey et al [18] in their prospective sur-
veillance of density of VRE in stool of colonized patients, which 
showed an expansion of VRE density in stool cultures of patients 
receiving antianaerobic antibiotic regimens, compared with those 
not receiving such regimens. Counterintuitively, gram-negative an-
tibiotic treatment has been associated with a doubled risk of bacte-
remia in ESBL-colonized patients [24]. Similarly, O’Fallon et al [17] 
noted that two-thirds of patients with persistent multidrug-resistant 
gram-negative bacterial colonization did not receive antibiotics 
during their prospective surveillance study, underscoring that 
factors other than antibiotics also drive colonization.
These observations point to complex interactions between 
healthy microbiota, AROs, and the host, which have been 
reviewed elsewhere [27]. Key examples of mechanisms of colo-
nization resistance include resistance to VRE colonization with 
defined bacterial consortia and with viral and viruslike Toll-like 
receptor simulation of the antimicrobial peptide Reg3γ [28, 
29]. Another established mechanism of colonization resistance 
is competition between commensals and potential pathogens 
for dietary and host-derived glycans and metabolites that are 
nutritional requirements [27]. As mechanisms of colonization 
resistance continue to be elaborated, FMT is being explored as 
a method to transfer these identified and unidentified ARO-
resistant factors to ARO-colonized patients.
FMT is the process of transplanting stool from a healthy 
donor to a diseased recipient. Practices similar to FMT have 
been traced to the Dong-jin dynasty of fourth-century China 
and reported in contemporary medical literature for treatment 
of pseudomembranous colitis in 1958 [30, 31]. Since a land-
mark randomized controlled trial of FMT for treatment of re-
current Clostridioides difficile infection (RCDI) was published 
in 2013, a number of clinical trials have demonstrated cure rates 
of approximately 90% when repeated FMTs are included [31–
35]. FMT has become an important treatment for RCDI and is 
included in major society guidelines including those produced 
by the Infectious Disease Society of America and a number of 
European professional societies [37, 38]. With increasing use of 
FMT for RCDI, loss of ARO colonization has been increasingly 
recognized as a collateral benefit in these patients and has been 
described in increasing numbers of case reports and case series.
EFFICACY OF INTESTINAL MICROBIOME THERAPIES 
FOR ARO DECOLONIZATION AMONG PATIENTS 
WITH RCDI
The use of FMT for RCDI expanded after publication of a Dutch 
randomized, controlled trial and the decision of the FDA to 
allow the use of FMT under an enforcement discretion policy in 
the United States. Some patients treated for RCDI were found 
to also be colonized with other AROs, and in some these AROs 
cleared after FMT (Table 1).
Stripling et  al [41] described the decreased intestinal rela-
tive abundance of VRE in a heart-kidney transplant recipient 
with RCDI and recurrent VRE infections treated with FMT. The 
potential confounding of stopping vancomycin used for RCDI 
treatment before FMT and decreased VRE relative abundance 
in stool was acknowledged as a limitation [41]. However, an 
increase in the relative abundance of genera that were differ-
entially abundant in donor stool, such as Blautia, Akkermansia, 
Rosburia, and Faecalibacterium, suggested a donor-derived ben-
efit [41]. In a secondary analysis of a phase II study of a human 
microbiota–derived product for treatment of RCDI, Dubberke 
et al [12] noted that 8 of 11 patients (73%) who were VRE posi-
tive at baseline were negative for VRE at the last follow-up stool 
culture. Using culture-independent techniques, Millan et al [45] 
demonstrated a significant reduction in the count of antibiotic 
resistance genes in the stool samples of patients with RCDI 
with each successive FMT treatment. Notably, not all published 
cases of RCDI and ARO colonization treated with FMT have 
demonstrated successful ARO decolonization. Jang et  al [39] 
described a patient with RCDI and VRE stool colonization who 
was persistently colonized with VRE after 2 FMTs.
EFFICACY OF FMT FOR ARO DECOLONIZATION AS 
PRIMARY OUTCOME
Case reports, case series, and prospective studies have also 
demonstrated the efficacy of FMT for ARO decolonization as 
a primary outcome (Table 2). These studies were informed by 
hypotheses of shared risk factors with RCDI and ARO coloni-
zation, mouse models, and secondary analyses of patients with 
RCDI treated with FMT and found to have ARO decolonization.
Multiple case reports have described loss of ARO coloni-
zation after treatment with FMT. Freedman and Eppes [46] 
described their clinical group’s eradication of carbapenem-
resistant Klebsiella pneumoniae colonization in a 14-year-old 
girl with hemophagocytic lymphohistocytosis and 5 weeks of 
persistently positive blood cultures with K. pneumoniae. Three 
follow-up stool cultures over an 8-month period were negative 
for K. pneumoniae and she had no recurrent infections over an 
18-month follow-up period [46]. Lagier et al [48] described the 
successful decolonization of a patient with intestinal coloniza-
tion with OXA-48 carbapenemase producing K.  pneumoniae. 
In both patients, treatment with FMT was motivated by major 
challenges presented by the ARO colonization. Although these 
were single case patients without controls, these findings sup-
port further testing of hypotheses that ARO decolonization 
with FMT could reduce ARO infection and improve care for 
patients with limited options [46, 48].
Bilinski et  al [49] reported the results of a prospective 
study of FMT for ARO colonization in 20 patients with leu-
kemia, multiple myeloma, and thrombotic thrombocytopenic 
purpura. Efficacy assessments were based on follow-up at 1 








niversity in St. Louis user on 14 O
ctober 2019










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































niversity in St. Louis user on 14 O
ctober 2019































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































niversity in St. Louis user on 14 O
ctober 2019
6 • ofid • Woodworth et al
no control group, and providers were permitted to prescribe 
antibiotics, as indicated by clinical circumstances. The de-
colonization end point was met in 15 of 25 FMTs (60%) at 
1 month and in 13 of 14 (93%) at 6 months, and Escherichia coli 
was decolonized with more efficacy than K. pneumoniae [49]. 
A subset analysis showed that patients treated with FMT and 
not prescribed antibiotics were more likely to reach the primary 
end point of no ARO colonization at 1 month than patients who 
were prescribed antibiotics [49].
Davido et al [13] reported outcomes of a French multicenter 
pilot clinical study of FMT for decolonization with CRE and/
or VRE. At 1 and 3 months, 2 of 8 patients (25%) and 3 of 8 
(38%), respectively, were decolonized [13]. The authors did 
not identify characteristics that distinguished patients who 
were decolonized at 1 month from those who were persistently 
colonized, and no patients who were VRE colonized at base-
line were decolonized at 1 month [13]. In a subsequent report 
from the same multicenter group in France, Dinh et  al [15] 
described similar decolonization proportions of 3 of 8 (38%) 
and 3 of 9 (33%) among CRE- and VRE-colonized patients, re-
spectively, at 1 week after FMT. At 3 months, 4 or 8 (50%) and 7 
of 8 (88%) CRE- and VRE-colonized patients, respectively, were 
decolonized. In these French studies, no adverse events were re-
ported, and there was no control group to compare the duration 
of ARO colonization.
Singh et al [50] completed a study of FMT for decoloniza-
tion of ESBL in 15 patients; when including patients who un-
derwent a second FMT for persistently ESBL-positive cultures, 
they found an overall decolonization rate of 40%. In their as-
sessment, those authors suggested that differential efficacy be-
tween 2 stool donors may have accounted for the differences in 
outcomes [50].
Effect of FMT for ARO Decolonization on Need for Contact Isolation
One study comparing 10 patients undergoing FMT to treat 
ARO colonization and 20 matched retrospective controls 
demonstrated a decrease of 21.5  days in the median delay to 
discharge [53]. These authors also reported a median decrease 
in time to decolonization, from 50.5 to 3 days [53]. Although 
discharge delays in this study were related to limitations in 
facilities that were able to receive ARO-colonized patients, these 
findings suggest that ARO decolonization with FMT could 
present major cost savings to healthcare systems. They also un-
derscore the potential public health impact of reducing trans-
mission of AROs between patients.
Effect of FMT on Frequency of Recurrent Infections Other Than RCDI
Studies have also described a potential benefit of breaking the 
cycle of recurrent urinary tract infections (RUTIs) after FMT 
for RCDI. Wang et  al [44] described an 83-year-old woman 
with a 25-year history of RUTIs who was treated with FMT for 
RCDI and had a complete cessation of RUTIs during 25 months 
of follow-up. A  similar observation was reported in a case-
control study of 8 patients with ≥3 RUTIs before FMT who 
were matched to controls with 3 episodes of C. difficile infection 
and ≥3 RUTIs not treated with FMT [43]. Patients with RUTIs 
treated with FMT were shown to have a decrease in urinary 
tract infections, from a median of 4 in the year before FMT to 1 
in the year after FMT. E. coli antimicrobial susceptibilities were 
noted to improve in the post-FMT setting for cephalosporins, 
fluoroquinolones, and trimethoprim-sulfamethoxazole [43].
Taken together, these findings show potential efficacy of FMT 
for decolonization of intestinal colonization with AROs. They 
have also suggested potential differences in decolonization fre-
quency by ARO type that could be related to pathogen-specific 
colonization factors. These studies do have important limita-
tions that should be addressed in future studies.
LIMITATIONS OF PUBLISHED STUDIES ON FMT FOR 
ARO DECOLONIZATION
Approaches for FMT for ARO decolonization are still early 
in development. Accordingly, there are still important limita-
tions in our understanding of the safety and efficacy of using 
FMT for this indication. Most published studies lacked control 
groups and long-term follow-up periods. They used varying 
definitions of decolonization and nonstandardized treatment 
protocols. These limitations restrict the generalizability of the 
findings. Central questions remain about whether findings of 
decolonization and decreased frequency of recurrent infections 
after FMT are directly related to FMT treatments, to other se-
lective pressures such as cessation of antibiotics, or to sponta-
neous decolonization events. The use of FMT outside healthcare 
settings, as in travelers returning from locales with higher prev-
alence of AROs, may also warrant further study.
Limited Data for Long-Term Safety 
A number of FMT case reports and series have described new 
diagnoses that were temporally associated with the administra-
tion of FMT. The intestinal microbiome has also been linked 
to colorectal cancer, atherosclerosis, and thrombosis [54, 55]. 
These reports have raised a number of concerns about the 
possible long-term metabolic, inflammatory and neoplastic 
risks related to FMT. Long-term prospective cohort studies are 
needed to further evaluate these potential risks.
Need for Mechanistic Studies and Control Groups in Clinical Trials of FMT 
for ARO Decolonization 
Preclinical studies have identified mechanisms of microbiome-
mediated ARO colonization resistance. For example, in the 
case of C.  difficile, bile-salt metabolism, gastrointestinal (GI) 
luminal pH, and competition for resources are known to be 
contributing factors in the development of infection [27]. 
Categories of AROs may occupy distinct spatial niches within 
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of FMT for treatment of RCDI have had control groups, to date 
only 1 published prospective clinical trial of FMT for ARO de-
colonization has included a control group [52]. The lack of a 
control group greatly weakens estimates of causal associations 
between FMT and ARO decolonization.
Need for Further Study of Clinical Failures to Improve Mechanistic 
Understanding
Many case reports and case series to date have described 
positive outcomes after FMT. However, the implicit risk of 
publication bias against negative results of FMT for ARO de-
colonization should be acknowledged. In 1 of the few studies 
published with mixed outcomes for FMT ARO decolonization, 
Stalenhoef et al reported the detailed clinical history, microbio-
logic, and microbiome analyses for a patient treated with FMT 
for Verona integron–encoded metallo-β-lactamase–producing 
Pseudomonas aeruginosa. This Pseudomonas isolate was not 
detected in the post-FMT setting, but an ESBL-producing 
E. coli was, which they describe as a clinical success combined 
with microbiologic failure [57]. They note that their patient 
had “intact” microbiota diversity before FMT and question the 
potential efficacy of FMT in patients with normal microbiota 
diversity. 
This potential issue was also observed in 2 negative studies of 
FMT that were conducted to estimate its efficacy in treating 
metabolic syndrome and chronic inflammation in virally 
suppressed patients with human immunodeficiency virus in-
fection [58, 59]. Diversity analyses describe the composition of 
a microbial community at a high level but do not clarify the 
functional capacity of these communities. It is also likely that 
FMT may not be effective for nonintestinal or non–genitouri-
nary tract reservoirs of colonization by ARO (eg, biliary or pul-
monary). New analytic tools and databases are being developed 
that allow analyses of the gene-predicted functional capacity 
of microbial communities with metagenomic whole-genome 
sequencing [60]. These tools support moving beyond diver-
sity measures alone and improved understanding of how taxa 
and their functional capacity may reduce ARO colonization. In 
turn, this could inform selection of minimal or ideal taxa to in-
clude in rationally developed microbiome therapeutics.
PRACTICAL QUESTIONS AND PRIORITIES TO 
IMPROVE FUTURE FMT CLINICAL STUDIES
In Table 3, we present a list of challenges, opportunities, and re-
search priorities to improve the current understanding of FMT 
for ARO decolonization. Although most studies published to 
date included FMT pretreatments with bowel lavage, with or 
without antibiotics (Tables 1 and 2), it is not clear whether this 
step improves efficacy. In a pragmatic study of a lyophilized, 
encapsulated FMT product taken orally, bowel lavage was aban-
doned after 4 patients, and the dose was decreased during the 
study period without a clear compromise in efficacy [61]. These 
and other practices, such as promotility medications and proton-
pump inhibitors coadministered with FMT when delivered via 
an upper GI tract route or antidiarrheals when administered 
via an enema, have not been validated in controlled studies. 
Evidence supporting these practices is generally at the level of 
Table 3. Proposed Practical Research Agenda for Future Study of Fecal Microbiota Transplantation for Antibiotic-Resistant Organism Decolonization
Existing Challenge Recommendations
Wide variability in FMT approaches in published literature Multicenter clinical trial consortia should be funded to reduce variability in research 
approaches, improve rigor and reproducibility, and streamline protocol development to 
study the following prospectively: 
Ideal feces donor characteristics for ARO decolonization 
FMT dosing frequency and thresholds for repeating treatment 
Risks/benefits of bowel-preparation, antibiotic pretreatment 
Differential effects on specific AROs 
FMT recipient host factors that modulate FMT efficacy 
Improve recruiting capacity for rare cases (extreme multidrug resistance) 
ARO detection in feces in control groups in setting of ongoing antibiotic pressure and varied 
place of residence 
Benefits to patients of tailored microbiome therapies of microbial consortia or rationally 
matched donors
Regulatory future of FMT remains unclear FDA, industry, and academics should work collaboratively to maintain patient-centered reg-
ulatory approaches that balance needs for further study with access to therapies with an 
immediate need
Unrefined end points of clinical studies Benchmarking studies are needed to compare the performance characteristics of culture-
based, culture-independent, and mixed methods that incorporate both approaches; 
measures of ARO decolonization should be studied to better estimate precision by 
number of consecutive swab samples, combining swab samples with PCR- or NGS-based 
techniques
Limited long-term safety outcomes data Long-term cohorts and registries are needed to study the long-term safety of microbiome 
therapeutics
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expert opinion [37]. These questions warrant additional inves-
tigation to improve the safety and efficacy of FMT as it becomes 
more commonly performed [62, 63].
Although a dose of ≥50 g of stool has been recommended, 
the ideal processing method and the size and frequency of the 
FMT dose have not been well established [37]. For example, 
in their study of FMT for ARO decolonization in patients 
with blood disorders, Bilinski et al [49] noted that none of the 
patients in their series, treated with 1-day FMT, had complete 
decolonization. It is important to consider whether stool proc-
essing steps are needed to preserve viruses, pH, metabolites, or 
anaerobic non–spore-forming bacteria. Many studies of FMT 
efficacy for ARO decolonization have analyzed outcomes with 
FMT denominators rather than patients. Although the optimal 
dose, route, preparation, and other FMT details are unresolved, 
analyzing outcomes with patients as a denominator may clarify 
the impact of patient-specific factors.
Regulatory, Ethical, and Practical Considerations
Important questions remain for providers and patients about 
the use of FMT for ARO decolonization. The regulatory status 
of FMT remains in flux, but currently the US FDA requires 
an approved investigational new drug application for all uses 
of FMT other than RCDI. For RCDI, the FDA has chosen to 
exercise enforcement discretion. This means that an investiga-
tional new drug application is not required but patients should 
provide consent informed by the discussion of potential risks 
and the investigational nature of FMT. The novelty of FMT has 
brought a host of new questions, including whether the mate-
rial used in FMT is of human origin, akin to a tissue, or if it 
is a drug that must be consistently manufactured with good 
manufacturing principles. In addition, naturally occurring 
substances cannot be patented, which has motivated isolation 
of variants or derivatives of stool or the active components of 
FMT to balance drug development costs. On the other hand, 
patient and FMT-provider advocacy groups have asserted that 
FMT should remain available in its current form, with access to 
public stool banks and without explicit FDA approval.
We encourage providers to continue to advocate for patients 
to ensure access to potentially effective therapies. In the mean-
time, FMT should not become the standard of care before the 
safety and efficacy of FMT is rigorously tested in prospective 
blinded, randomized, controlled trials. Partnership with the 
FDA for investigational new drug applications, institutional re-
view boards, academics, ethicists, and industry will be neces-
sary for further development of these therapies.
CONCLUSIONS
The intestinal microbiome is a potentially promising target 
to directly reduce ARO colonization and possibly subsequent 
ARO infection. Early evidence suggests that FMT may have 
the potential to reduce ARO colonization by restoring micro-
bial community composition and function, but further study 
is necessary. We have outlined a practical research agenda that 
we believe will improve our current understanding of the safety 
and efficacy of FMT for ARO colonization and may improve 
patient care.
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